Expanding the therapy options for diabetic kidney disease

Affiliations

¹ Internal Medicine 3, Department of Medicine, University of Padova, Padova, Italy. Paola.fioretto@unipd.it.
² Department of Internal Medicine, University of Genoa and IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Paola Fioretto et al. Nat Rev Nephrol. 2022 Feb.

. 2022 Feb;18(2):78-79.

doi: 10.1038/s41581-021-00522-3.

¹ Internal Medicine 3, Department of Medicine, University of Padova, Padova, Italy. Paola.fioretto@unipd.it.
² Department of Internal Medicine, University of Genoa and IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

No abstract available

References

1. Wheeler, D. C. et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 9, 22–31 (2021). - DOI
1. Heerspink, H. J. L. et al. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 9, 743–754 (2021). - DOI
1. Jongs, N. et al. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 9, 755–766 (2021). - DOI
1. Droebner, K. et al. Direct blood pressure-independent anti-fibrotic effects by the selective nonsteroidal mineralocorticoid receptor antagonist finerenone in progressive models of kidney fibrosis. Am. J. Nephrol. 52, 588–601 (2021). - DOI
1. Bakris, G. L. et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 383, 2219–2229 (2020). - DOI